טוען...

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

BACKGROUND: CFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary objectives of this first-in-human phase 1 trial were to establish the safety and tolerability of CFI-400945 in patients with advanced solid tumours. Secondary objectiv...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	Br J Cancer
Main Authors:	Veitch, Zachary W., Cescon, David W., Denny, Trisha, Yonemoto, Lisa-Maria, Fletcher, Graham, Brokx, Richard, Sampson, Peter, Li, Sze-Wan, Pugh, Trevor J., Bruce, Jeffrey, Bray, Mark R., Slamon, Dennis J., Mak, Tak W., Wainberg, Zev A., Bedard, Philippe L.
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Publishing Group UK 2019
נושאים:	Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6738068/ https://ncbi.nlm.nih.gov/pubmed/31303643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0517-3
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

פריטים דומים